[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,192
Citations 0
Invited Commentary
August 1, 2019

Circulating Tumor DNA as a Marker for Disease Relapse in Early-Stage Breast Cancer—Bad Blood

Author Affiliations
  • 1The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 2Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee
JAMA Oncol. 2019;5(10):1479-1480. doi:10.1001/jamaoncol.2019.2047

Breast cancer is the most common cancer diagnosed in women worldwide and the second most common cancer diagnosed overall. Studies1,2 have found that most patients with early-stage disease will be cured, but there is a significant risk of both early and late recurrences. All treatments for breast cancer have some associated risks and adverse effects, some of which are permanent. Therefore, it is essential to develop methods to avoid overtreatment of patients by identifying those who are and are not at risk for relapse.